News

Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority

Osmetech has submitted a request to the FDA for emergency use authorization for its respiratory pathogen test panel test to be used to screen for the swine flu

Nerviano Medical Sciences, an Italian pharmaceutical R&D facility, has received FDA approval for its investigational new drug application to begin a Phase I clinical study with the company’s

Quest Diagnostics, a provider of diagnostic testing, information and services, has reported that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction

US-based pharmaceutical company Dara BioSciences has reported positive results from a Phase IIa clinical trial of KRN5500 for treatment of neuropathic pain in patients with advanced cancer. KRN5500

Targacept, a biopharmaceutical company, has reported preliminary results showing that AZD3480 met the primary outcome measure in a Phase II clinical study in adults with attention deficit hyperactivity

St Jude Medical, a medical device company, has announced the European CE Mark approval and first use of its EnSite Velocity cardiac mapping system. The EnSite Velocity System

GlaxoSmithKline has received the FDA’s approval for Lamictal ODT orally disintegrating tablets. Lamictal ODT uses a novel drug-delivery formulation to provide Lamictal in a tablet that has a

Swiss healthcare company Cardiola has received CE Mark recertification to market its m.pulse system for at-home use to treat chronic heart failure. Cardiola’s m.pulse system, based on Muscular